<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03622892</url>
  </required_header>
  <id_info>
    <org_study_id>NID ( 29BRC18.0055)</org_study_id>
    <nct_id>NCT03622892</nct_id>
  </id_info>
  <brief_title>Non-invasive Prenatal Diagnosis of Monogenic Disorders by Linked-reads Technology</brief_title>
  <acronym>NID</acronym>
  <official_title>Universal Haplotype-Based Non Invasive Prenatal Diagnosis by Linked-Read Sequencing (10XGenomics™ Technology)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Brest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Brest</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Description of the presence of cell-free fetal DNA in maternal plasma allowed the possibility&#xD;
      of non-invasive prenatal diagnosis. Whereas detection of paternally-inherited alleles is&#xD;
      straightforward and being quickly implemented in routine, detection of maternally-inherited&#xD;
      alleles remains challenging.&#xD;
&#xD;
      To date, the main approach that is being developped, called Relative Haplotype Dosage&#xD;
      Analysis, relies on the identification of an allelic imbalance between the mother's wild-type&#xD;
      and mutant alleles, relative to the fetal's contribution. This approach therefore requires&#xD;
      the study of a propositus to identify the morbid haplotype, which is not always possible in&#xD;
      the context of an ongoing pregnancy.&#xD;
&#xD;
      In this study, we aim to evaluate the contribution of new technologies, such as linked-read&#xD;
      Sequencing, to allow direct identification of parental haplotype in the context of&#xD;
      non-invasive prenatal diagnosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives:&#xD;
&#xD;
      The description of cell-free fetal DNA in maternal plasma offered the possibility of a non&#xD;
      invasive approach for prenatal diagnosis (Non Invasive Prenatal Diagnosis, NIPD). However,&#xD;
      only a small fraction of total cell-free DNA is of fetal origin, and its study widened only&#xD;
      recently with the development of new technologies, such as digital PCR and Massively Parallel&#xD;
      Sequencing.&#xD;
&#xD;
      Circulating fetal cells (CFC) represent a promising approach, but need further development&#xD;
      before routine implementation To date, clinical applications are limited to Non Invasive&#xD;
      Prenatal Testing for fetal aneuploidy and non invasive detection of fetal-specific genomic&#xD;
      regions, for example fetal sex determination or fetal RHD genotyping, or more recently de&#xD;
      novo mutations that can be suspected after echographic findings, such as achondroplasia. Yet,&#xD;
      NIPD of maternally-inherited monogenic diseases remains challenging, for the fetal allele is&#xD;
      hidden within a large amount of identical maternal sequences. Some publications report&#xD;
      successful NIPD of maternally-inherited monogenic diseases, but only on case reports or small&#xD;
      cohorts, without a standardized protocol and control of statistical risks.&#xD;
&#xD;
      In this study, we aim :&#xD;
&#xD;
        -  to develop a new non invasive approach to Prenatal Diagnosis using both direct and&#xD;
           indirect strategy by Massively Parallel Sequencing,&#xD;
&#xD;
        -  to identify and characterize CFC.&#xD;
&#xD;
      Methods:&#xD;
&#xD;
      We recently acquired the Chromium™ technology (10XGenomics™). This approach, relying on&#xD;
      microfluidic-based linked-read sequencing, allows direct haplotype phasing from long input&#xD;
      DNA molecules, in this case parental genomic DNA. It is therefore possible to identify the&#xD;
      mutant-linked haplotype for each parent and deduce fetal status with concomitant plasma DNA&#xD;
      analysis.&#xD;
&#xD;
      We plan to include couples at risk of transmitting cystic fibrosis, during genetic counseling&#xD;
      for prenatal diagnosis (PND). Non invasive analysis will be performed concomitantly to&#xD;
      conventional PND, which will be performed on invasive fetal sample. After sequencing, we will&#xD;
      use a new analysis algorithm that allows strict control of statistical risk.&#xD;
&#xD;
      Furthermore, we plan on using the Chromium Single Cell Solution (10XGenomics™) to isolate&#xD;
      CFC. This approach allows analysis of single cell gene expression from thousands cells in a&#xD;
      sample.&#xD;
&#xD;
      Expected results:&#xD;
&#xD;
      In this first study, we wish to include 20 couples in the course of 12 months, which will&#xD;
      represent the largest cohort published to date.&#xD;
&#xD;
      We aim to assess feasibility of this new promising technology of Universal Haplotyping by&#xD;
      linked-read sequencing in the context of NIPD of monogenic diseases, in terms of result&#xD;
      accuracy as well as analysis time and technical cost. This straightforward protocol opens&#xD;
      perspectives for a first-intention non invasive approach of prenatal diagnosis of familial&#xD;
      monogenic diseases.&#xD;
&#xD;
      The Single Cell Solution will also enable us to differentiate the cell types circulating in&#xD;
      maternal blood, and to identify molecular markers to isolate CFC.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">October 18, 2018</start_date>
  <completion_date type="Anticipated">October 18, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 18, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Non-invasive Prenatal Diagnosis of Monogenic Disorders</measure>
    <time_frame>3 years</time_frame>
    <description>Development of a robust and standardized NIPD protocol relying on Relative Haplotype Dosage Analysis after deciphering of parental haplotype by Linked-Read Sequencing</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Description of Circulating Fetal Cells</measure>
    <time_frame>3 years</time_frame>
    <description>Use of the 10X Genomics* Single Cell Solution to identify Circulating Fetal Cells and describe their transcriptional characteristics in order to develop a cell-based Non Invasive Prenatal Diagnosis</description>
  </secondary_outcome>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Cystic Fibrosis</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Parental DNA Maternal cell-free DNA&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Couples at 25% risk of transmitting Cystic Fibrosis and asking for prenatal diagnosis for&#xD;
        this indication in the pluridisciplinary centers of Brest, Nantes, Dijon or Rouen&#xD;
        University Hospitals, France.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pregnancies at 25% risk of being affected by Cystic Fibrosis with previously&#xD;
             identified pathogenic variants&#xD;
&#xD;
          -  Couple asking for invasive prenatal diagnosis&#xD;
&#xD;
          -  Pregnancy at 8 weeks of gestation or later&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Couple not asking for prenatal diagnosis&#xD;
&#xD;
          -  No signed consent obtained&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claude Ferec, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>CHU de Brest</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Claude Ferec, MD, PhD</last_name>
    <phone>0033298444138</phone>
    <email>claude.ferec@chu-brest.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mathilde Pacault, MD</last_name>
    <phone>0033229020150</phone>
    <email>mathilde.pacault@chu-brest.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHRU de Brest</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claude Ferec</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU de Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christel Thauvin-Robinet, MD, PhD</last_name>
      <phone>0033380293489</phone>
      <email>christel.thauvin-robinet@chu-dijon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marie Vincent, MD</last_name>
      <phone>0033240083245</phone>
      <email>marie.vincent@chu-nantes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvie Odent</last_name>
      <email>Sylvie.odent@chu-rennes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Rouen</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anne-Marie Guerrot, MD</last_name>
      <phone>0033232888747</phone>
      <email>anne-marie.guerrot@chu-rouen.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Saint Brieuc</name>
      <address>
        <city>Saint-Brieuc</city>
        <zip>22000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mélanie Fradin</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>August 6, 2018</study_first_submitted>
  <study_first_submitted_qc>August 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2018</study_first_posted>
  <last_update_submitted>January 24, 2020</last_update_submitted>
  <last_update_submitted_qc>January 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non Invasive Prenatal Diagnosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

